Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Real-World Experience of Asciminib: Factors Associated with Response

Blood (2022) 140 (Supplement 1): 6796–6797.

https://doi.org/10.1182/blood-2022-165501

Published: 2022

Journal Articles

Challenging the Concept of Triple-Negative Thrombocytosis: Real-World Evidence from a Single Institution Experience

Ali Mahdi, Sahil Bhagat, Grace Langford, Rebecca Frewin, Eamon Mahdi

Blood (2022) 140 (Supplement 1): 12250–12251.

https://doi.org/10.1182/blood-2022-165480

Published: 2022

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Andreas Reiter, MD, Gunay Ahmadova, MD, Mohamad Jawhar, MD, Andres Virchis, MD, Tim Somervaille, MDPhD, Mark Williams, MD, Bernd Schönberger, MD, Rebecca Frewin, FRCPath, MRCP, MBBS, BSc, Philipp J. Jost, MD, Annett Maschke, MD, Peter Keller, MD, Torsten Haferlach, MD, Nicole Naumann, Juliana Schwaab, MD, Alice Fabarius, PhD, Wolf-Karsten Hofmann, MD, Claudia Haferlach, MD, Nicholas C.P. Cross, PhD, Georgia Metzgeroth, MD

Blood (2016) 128 (22): 3114.

https://doi.org/10.1182/blood.V128.22.3114.3114

Published: 2016

NARROW

Real-World Experience of Asciminib: Factors Associated with Response

Challenging the Concept of Triple-Negative Thrombocytosis: Real-World Evidence from a Single Institution Experience

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Real-World Experience of Asciminib: Factors Associated with Response

Challenging the Concept of Triple-Negative Thrombocytosis: Real-World Evidence from a Single Institution Experience

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Clinical Characteristics and Treatment with Various Tyrosine Kinase Inhibitors in Patients with ETV6-ABL1 positive Eosinophilia-Associated Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only